Cellectis: Monthly Information on Share Capital and Company Voting Rights
09 January 2018 - 8:30AM
Business Wire
(Article 223-16 of General Regulation of the
French financial markets authority)
Regulatory News:
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20180108006107/en/
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: NYSE Euronext Paris
ISIN code: FR0010425595
Date
Total number of shares
in the capital
Total number of voting
rights
12/31/2017 35,928,189 41,083,524
About CellectisCellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of
cancer immunotherapies based on gene-edited T-cells (UCART). By
capitalizing on its 18 years of expertise in gene editing – built
on its flagship TALEN® technology and pioneering electroporation
system PulseAgile – Cellectis uses the power of the immune system
to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.Cellectis is listed
on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS). To find out more about us, visit our website:
www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
DisclaimerThis press release contains “forward-looking”
statements that are based on our management’s current expectations
and assumptions and on information currently available to
management. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Further information on
the risks factors that may affect company business and financial
performance, is included in filings Cellectis makes with the
Security Exchange Commission from time to time and its financial
reports. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new
information becomes available in the future.
###
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180108006107/en/
CellectisMedia:Jennifer Moore, 917-580-1088VP of
Communicationmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2023 to May 2024